Shrestha UK. Emerging role of artificial intelligence in gastroenterology and hepatology. World J Gastroenterol 2025; 31(39): 111495 [DOI: 10.3748/wjg.v31.i39.111495]
Corresponding Author of This Article
Umid K Shrestha, MD, Professor, Department of Gastroenterology and Hepatology, Nepal Mediciti Hospital, Bhaisepati, Ward No. 18, Lalitpur 44700, Bagmati, Nepal. umidshrestha@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Oct 21, 2025 (publication date) through Oct 21, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Shrestha UK. Emerging role of artificial intelligence in gastroenterology and hepatology. World J Gastroenterol 2025; 31(39): 111495 [DOI: 10.3748/wjg.v31.i39.111495]
World J Gastroenterol. Oct 21, 2025; 31(39): 111495 Published online Oct 21, 2025. doi: 10.3748/wjg.v31.i39.111495
Emerging role of artificial intelligence in gastroenterology and hepatology
Umid K Shrestha
Umid K Shrestha, Department of Gastroenterology and Hepatology, Nepal Mediciti Hospital, Lalitpur 44700, Bagmati, Nepal
Author contributions: Shrestha UK contributed to the conceptualization and design, writing the original draft, and reviewing and editing.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Umid K Shrestha, MD, Professor, Department of Gastroenterology and Hepatology, Nepal Mediciti Hospital, Bhaisepati, Ward No. 18, Lalitpur 44700, Bagmati, Nepal. umidshrestha@gmail.com
Received: July 1, 2025 Revised: July 28, 2025 Accepted: September 9, 2025 Published online: October 21, 2025 Processing time: 112 Days and 17.1 Hours
Abstract
Artificial intelligence (AI) has emerged as a transformative tool in the diagnosis and management of gastrointestinal (GI) and liver diseases. In clinical practice AI consists of overlapping technologies such as machine learning (ML), deep learning, natural language processing, computer vision, and generative AI. ML is a computer learning system that can provide insight into disease risk factors and phenotypes. Deep learning is an advanced and complex form of ML, structured with different levels of specific algorithms known as convolutional neural networks that can rapidly and accurately process unstructured, high-dimensional data, such as texts, images, and waveforms. Natural language processing is dedicated to facilitating interactions between computers and humans using natural language and helps to analyze, understand, and derive actionable information from unstructured healthcare data, including electronic health records, clinical notes, medical literature, and patient-generated content. Computer vision focuses on enabling computers to see and interpret images and videos and serves as an augmentation tool for endoscopists, improving accuracy and decreasing procedural time. Generative AI is capable of creating new forms of content by learning from a large body of data in the form of text, audio, images, or video and includes large language models. AI has been used in several GI diseases such as esophageal neoplasia, gastric cancer, Helicobacter pylori infection, gastritis, GI stromal tumors, colorectal polyps, inflammatory bowel disease, irritable bowel syndrome, GI bleeding, and pancreatobiliary diseases. The potential applications of AI in liver diseases encompass a variety of conditions such as liver masses, metabolic dysfunction-associated steatotic liver disease, viral hepatitis, cirrhosis, and liver transplantation. This review discussed the common terminologies and the current status of AI in gastroenterology and hepatology, exploring its applications and ethical issues.
Core Tip: Artificial intelligence (AI) has emerged as an invaluable transformative tool in diagnosis and management of gastrointestinal and liver diseases. In clinical practice AI technologies such as machine learning, deep learning, natural language processing, computer vision, and generative AI have been used in their applications. There is a need for continued development, validation, and real-world modeling of AI systems before its widespread adoption. Although it does not replace human clinical judgement, it can still be expected that AI application in gastroenterology and hepatology will further be enhanced in the future and become the standard of care in clinical practice.